Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: AGEN
- CUSIP: 00847G70
- Previous Close: $3.85
- 50 Day Moving Average: $4.024
- 200 Day Moving Average: $5.134
- 52-Week Range: $2.73 - $7.49
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.05
- P/E Growth: 0.000
- Market Cap: $335.00M
- Outstanding Shares: 87,126,000
- Beta: 2.51
- Net Margins: -472.80%
- Return on Equity: -359.98%
- Return on Assets: -47.88%
Companies Related to Agenus:
- Debt-to-Equity Ratio: -6.00%
- Current Ratio: 3.14%
- Quick Ratio: 3.14%
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
Where is Agenus' stock going? Where will Agenus' stock price be in 2017?
5 analysts have issued twelve-month price targets for Agenus' shares. Their predictions range from $5.00 to $15.00. On average, they anticipate Agenus' share price to reach $9.80 in the next year.
When will Agenus announce their earnings?
Agenus is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
What are analysts saying about Agenus stock?
Here are some recent quotes from research analysts about Agenus stock:
According to Zacks Investment Research, "Agenus focuses on the development of checkpoint modulators, vaccines and adjuvants for cancer treatments. With no approved product in its portfolio, the company is heavily dependent on its collaborators for top-line growth. In addition, the company is dependent on its partners for pipeline development. Moreover, Agenus has few candidates in mid-stage of development including Prophage vaccine and several QS-21 Stimulon-containing vaccine candidates. Any unfavorable outcome from the studies may affect the company’s shares adversely. However, the company received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. Moreover, the company’s collaboration agreements provide a steady source of funds. Agenus’ shares have outperformed the Medical/Biomedical Genetics industry." (12/27/2016)
Maxim Group analysts commented, "Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33)." (7/28/2016)
Who owns Agenus stock?
Agenus' stock is owned by many different of institutional and retail investors. Top institutional investors include RTW Investments LP (4.83%), State Street Corp (4.02%), FMR LLC (1.86%), Marshall Wace LLP (0.57%), Allianz Asset Management AG (0.28%) and Bruce & Co. Inc. (0.18%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal, Shahzad Malik and Ulf Wiinberg.
Who sold Agenus stock? Who is selling Agenus stock?
Agenus' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Allianz Asset Management AG and Metropolitan Life Insurance Co. NY.
Who bought Agenus stock? Who is buying Agenus stock?
Agenus' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, Glenview Trust Co, Perceptive Advisors LLC, RTW Investments LP, AQR Capital Management LLC, A.R.T. Advisors LLC and First Allied Advisory Services Inc.. Company insiders that have bought Agenus stock in the last two years include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg.
How do I buy Agenus stock?
Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Agenus stock cost?
One share of Agenus stock can currently be purchased for approximately $3.85.